This paper could sound the death knell for subjective visual assessment of cerebrospinal £uid (CSF) spectral scans from zero-order derivatives upwards. It has taken a quantitative approach to the measurement of the small amounts of bilirubin which leak into the CSF after a haemorrhage by using the time honoured Jendrassik^Grof diazo method modi¢ed to increase the sensitivity of detection. The analysis was automated and used a four-fold increase in specimen:reagent volume and calibrated up to 10 500 nmol/L and the results compared with the spectral scans. The detection limit was 35 nmol/L but the within-run CV at 100 nmol/L was high at 20%. Haemoglobin did not interfere in the quantitative method up to a concentration of 10mg/dL but higher concentrations were associated with negative absorbance. The mean bilirubin in the CSF of patients not suspected of having subarachnoid haemorrhage was 234 nmol/L give or take1sd of 62 nmol/L. Using a cut-o¡ of 359 nmol/L re£ecting the mean and 2 sd, the sensitivity and speci¢city of the quantitative assay compared to spectrophotometry was 100 and 92% respectively. Correction for net bilirubin absorbance is also required for the quantitative assay. The authors advocate the utility of the modi¢ed diazo reaction for CSF bilirubin quantitation to screen for xanthochromia with a spectrophotometric scan, to follow up those specimens with quantitative results greater than 359 nmol/L.
This paper could sound the death knell for subjective visual assessment of cerebrospinal £uid (CSF) spectral scans from zero-order derivatives upwards. It has taken a quantitative approach to the measurement of the small amounts of bilirubin which leak into the CSF after a haemorrhage by using the time honoured Jendrassik^Grof diazo method modi¢ed to increase the sensitivity of detection. The analysis was automated and used a four-fold increase in specimen:reagent volume and calibrated up to 10 500 nmol/L and the results compared with the spectral scans. The detection limit was 35 nmol/L but the within-run CV at 100 nmol/L was high at 20%. Haemoglobin did not interfere in the quantitative method up to a concentration of 10mg/dL but higher concentrations were associated with negative absorbance. The mean bilirubin in the CSF of patients not suspected of having subarachnoid haemorrhage was 234 nmol/L give or take1sd of 62 nmol/L. Using a cut-o¡ of 359 nmol/L re£ecting the mean and 2 sd, the sensitivity and speci¢city of the quantitative assay compared to spectrophotometry was 100 and 92% respectively. Correction for net bilirubin absorbance is also required for the quantitative assay. The authors advocate the utility of the modi¢ed diazo reaction for CSF bilirubin quantitation to screen for xanthochromia with a spectrophotometric scan, to follow up those specimens with quantitative results greater than 359 nmol/L. Diagnosing sub-clinical disease is di⁄cult, particularly when the disorder cannot be de¢ned clearly by symptoms. Surks and his 12 co-authors were expert panelists at a consensus conference in September 2002 which reviewed the literature using keywords from between 1995^2002. They found 195 articles on sub-clinical thyroid disease, and they detailed the de¢cits in knowledge related to the de¢nition, epidemiology, consequences, treatment and evaluation of sub-clinical hypothyroidism and sub-clinical hyperthyroidism. The quality of evidence was rated according to the US Preventive Services Task Force criteria.
Sub-clinical thyroid disease is a laboratory diagnosis, de¢ned using serum TSH results alone. The clinical biochemistry laboratory therefore has an important role in monitoring the performance of serum TSH assays, particularly the functional sensitivity. Investigation into borderline elevations and decreases of serum TSH is required to eliminate artefacts, non-thyroidal illness, drug and treatment e¡ects. The panel of authors made an evidence-based de¢nition of the euthyroid reference range for serum TSH of 0.45 to 4.5 mu/L.
The evidence for a range of possible consequences of sub-clinical thyroid disease such as cardiac dysfunction, elevations in serum cholesterol, systemic symptoms and alterations in bone density was evaluated. Two groups were de¢ned for each subclinical disease on the basis of the serum TSH concentration; 4.5^10 mu/L, and greater than 10 mu/L for subclinical hypothyroidism, and less than 0.1mu/L and 0.1^0.45 mu/L for subclinical hyperthyroidism. Because of good evidence for the progression from sub-clinical hypothyroidism to overt hypothyroidism with a serum TSH of greater than 10 mu/L, treatment was recommended. Patients with a serum TSH of less than 0.1mu/L and Graves' disease or nodular thyroid disease should be considered for treatment. Due to the lack of evidence, patients in high-risk groups (age greater than 60 years, at high risk of heart disease, osteopenia or osteoporosis, or with hyperthyroid symptoms, young people) with a serum TSH of less than 0.1mu/L should have treatment decisions made on an individual basis. Patients falling into the other groups (serum TSH between 4.5^10 mu/L or 0.1^0.45 mu/L) should have serum TSH monitored at regular intervals, as the evidence was either insu⁄cient or there was no evidence for any bene¢t of treatment. Serum TPO measurement was not advised.
The panel recommended aggressive case-¢nding in women older than 60 years of age, in individuals with a previous history of thyroid disease or treatment, those with type I diabetes mellitus, autoimmune disease, atrial ¢brillation or a family history of thyroid disease. Population screening, even in pregnancy, was not recommended. Journal Watch clinical applications of the guidelines are placed in context using ¢ve clinical cases where management of sub-clinical thyroid disease is delineated. Two simpli-¢ed clinical £ow-charts aid the understanding of these complex problems.
In summary, there is little data to support an association between sub-clinical thyroid disease with symptoms, adverse clinical outcomes or bene¢ts of treatment. The authors recommend against routine treatment of patients with serum TSH concentrations within the ranges 0.1^0.45 mu/L and 4.5^10.0 mu/L. The potential bene¢ts and harms in newborn screening for cystic ¢brosis (CF) have long been debated. Screening has been undertaken in Australia and parts of Europe for some time and is due to be rolled out in England. Comeau and her colleagues report at length on the implementation in New England of what has become the usual two-tier screening protocol. This protocol ¢rst measures immunoreactive trypsin (IRT) in the dried blood spot followed by DNA analysis for a panel of CF mutations in those samples above the IRT cut-o¡. Infants thus identi¢ed with one or two mutations are referred to a paediatrician for a de¢nitive diagnosis by sweat testing. They introduced a failsafe step in that those infants with highly elevated IRTs (499.8%) but in whom no mutations were found were also referred for a sweat test. This maximizes CF detection in ethnic populations whose mutations are not represented in the common mutations panels, which tend to be of largely northern European origin.
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Over a 4-year period 323506 infants (98.4% of newborns) were sampled at about 2 days of age. For the ¢rst 9 months IRTs 490th daily percentile prompted DNA analysis and for the rest of the study this was adjusted to 495th daily percentile. Also after 21 months their mutation panel increased from 16 to 27 mutations.
Samples from 19 070 (5.9%) infants were analysed for CF mutations following an elevated IRT assay. One or two mutations were found in 1011 leading to the diagnosis of CF in 110. The failsafe procedure lead to a further 327 additional sweat tests identifying two (0.6%) Hispanic cases. Two false negatives were reported, one of whom presented with meconium ileus, known to be associated with lower IRT values.
The main point of interest in this paper is the di¡erent approach to screening in the States. In Europe and Australia screening laboratories aim for maximum sensitivity and minimum false positives. An IRT cut-o¡ of the top 0.5% rather than 5.0% employed by the New England centre would have provided similar sensitivity but with only about10% of the carriers being identi¢ed. This would have raised the positive predictive value of the screen from 8.2% to about 50%.
Given the large number of 1228 non-CF infants identi¢ed by this programme, there is no mention of how the inevitable anxiety of their parents was addressed and no discussion as to the suitability of the IRT cut-o¡ chosen. Devising protocols for handling carriers has been a major factor impeding the extension of CF screening in England.
